David Schenkein
About David Schenkein
David Schenkein: Board Director
David Schenkein is a seasoned Board Director with extensive experience in the life sciences sector. He is currently a member of the Board of Directors for multiple companies, including Denali Therapeutics, Agios Pharmaceuticals, Treeline Biosciences, Prime Medicine, Aera Therapeutics, and Leyden Labs. His governance roles extend over a variety of biotech and pharmaceutical firms, reflecting his broad expertise and leadership capabilities.
David Schenkein's Education and Expertise
David Schenkein holds a B.A. in chemistry from Wesleyan University and an M.D. from the State University of New York Upstate Medical School. With over 30 years of experience as a hematologist and medical oncologist, he has demonstrated expertise in therapeutics, diagnostics, medical devices, novel care delivery systems, and payer innovation. His educational background and professional experiences have equipped him with deep insights into the medical and life sciences fields.
David Schenkein's Professional Background
David Schenkein has a rich professional background, spanning roles in academia and industry. He served as an adjunct Clinical Professor of Medical Oncology at Stanford University School of Medicine and is currently an Adjunct Attending Physician in Hematology at Tufts Medical Center. He spent significant years in leadership roles, including 10 years as CEO and a member of the Board of Directors at Agios Pharmaceuticals and as Senior Vice President of Clinical Hematology/Oncology at Genentech. Furthermore, he was Senior Vice President of Clinical Research at Millennium Pharmaceuticals.
David Schenkein's Role at Genentech
During his tenure as Senior Vice President of Clinical Hematology/Oncology at Genentech, David Schenkein led the medical and scientific strategies for Genentech's BioOncology portfolio. He was responsible for numerous successful oncology drug approvals, which significantly contributed to Genentech's reputation in the oncology space. His strategic vision and leadership in clinical development helped advance several key therapeutics through the regulatory pipeline.
David Schenkein's Achievements at Millennium Pharmaceuticals
At Millennium Pharmaceuticals, David Schenkein served as Senior Vice President of Clinical Research. He oversaw the clinical development and worldwide approval of Velcade®, a breakthrough treatment in oncology. His role was pivotal in advancing Velcade® from clinical trials to global regulatory approval, marking a significant achievement in his career and contributing to advancements in cancer treatment.